The molecular mechanisms by which P. knowlesi and P. vivax invade human red blood cells have long been studied. Malaria parasite erythrocytic stages comprise of repeated bursts of parasites via cyclical invasion of host RBCs using dedicated receptor-ligand interactions. A family of erythrocyte-binding proteins (EBPs) from P. knowlesi and P. vivax attach to human Duffy antigen receptor for chemokines (DARC) via their Duffy binding-like domains (Pv-DBL and Pk-DBL respectively) for invasion. Here, we provide a comprehensive overview that presents new insights on the atomic resolution interactions that underpin the binding of human DARC with Pk/Pv-DBLs. Based on extensive structural and biochemical data, we provide a novel, testable and overarching interaction model that rationalizes even contradictory pieces of evidence that have so far existed in the literature on Pk/Pv-DBL/DARC binding determinants.
Introduction
Engagement of specific host receptors with parasite-encoded ligands between human RBCs and malaria parasite surface proteins is a key event in invasion of merozoites into erythrocytes (Cowman et al., 2017) . The signature Duffy-binding like domain (DBL) is present in parasiteencoded erythrocyte binding proteins (EBPs) and in protein families like P. falciparum EMP1s (Cowman et al., 2017) . The latter are part of the var gene family where they assist in cytoadherencethese contain several copies of DBLs in each protein, whereas the P. falciparum EBP named EBA-175 harbors two copies (F1 and F2) of DBLs. In contrast EBPs of P. knowlesi and P. vivax contain only single DBL each. There are multiple EBPs present in the malaria parasite P. knowelsi (α, β and γ), and it is the Pkα-DBL and Pv-DBL that mediate DARCdependent invasion of erythrocytes in rhesus and humans (Chao et al., 2005; Hans et al., 2005;  Chitnis & Sharma 2008); a subject of discussion in this review. Other DBL variants of P.
knowelsi EBPs: β and γ likely use alternate receptors on rhesus/human erythrocytes and may mediate invasion by Duffy antigen-independent pathways (Chitnis et al., 1994) . The Pk/Pv-DBLs (as part of their EBPs) are present on merozoite surface and are responsible for binding to the DARC receptor on reticulocytes, and thence mediating junction formation that is vital for the parasite invasion process (Adams et al., 1990; Adams et al., 1992; Cowman et al., 2006) (Fig. 1) .
The Pk/Pv-DBLs specifically recognize DARC's extracellular domain and its sulfated tyrosines via intermolecular interactions (Choe et al., 2005; de Breven et al., 2005; Chitnis & Sharma 2008) . Pk/Pv-DBLs are organized into three sub-domains and are typified (mostly) by twelvecysteine residues that are disulfide linked (Singh et al., 2003; Singh et al., 2006) . The importance of Pv -DBL/DARC pairing is underscored by human genetic data where DARC negative individuals tend to be protected from P. vivax infection (Ryan et al., 2006; Cavasini et al., 2007; Menard et al., 2010; King et al., 2011) . Contrary to the established DBL-DARC invasion pathway, there is evidence for DARC-independent invasion pathway in case of P. vivax infections, calling for new perspectives in assessing the utility of DARC recognizing Pv-DBL as a P. vivax vaccine candidate (Wurtz et al., 2011; Ntumngia et al., 2016) .
DARC is a seven transmembrane protein present on surface of erythrocytes and endothelial cells (Cowman et al., 2017) (Fig 1) . It is a promiscuous cytokine/chemokine receptor involved in proinflammatory processes of the immune system (Rot et al., 2004; Cowman et al., 2017) . DARC is also used as an entry vehicle by malaria parasites P. knowelsi and P. vivax (Pk/Pv) (Miller et al., 1975; Miller et al., 1976; Chitnis & Sharma 2008) (Fig. 1 ). The DARC regions spanning its soluble domain from 1-60 contain two key tyrosyl residues at positions 30 and 41, whose posttranslational modifications in the form of sulfation has been reported (Choe et al., 2005) . The binding requirements on DARC for Pv-DBL interaction have also been described (Choe et al., 2005; Tournamille et al., 2005) . Critical Pv-DBL binding residues have been mapped to an Nterminal 3 region of DARC (Tournamille et al., 2005) . Furthermore, sulfation of DARC at residues Tyr30 and Tyr41 has been strongly advocated as a key parameter for its high affinity coupling to Pv-DBL, where Tyr41 was shown to be the principal motif (Choe et al., 2005) .
Binding sites on Pk/Pv-DBLs for sulfated tyrosines of DARC
The Pk/Pv-DBLs and their three subdomains contain numerous disulfide linked cysteine residues that are largely conserved and these likely contribute to their structural integrity (Singh et al., 2003; Singh et al., 2006) . Conservation of hydrophobic residues and variance in solvent exposed residues within DBLs possibly allows for a parasite-specific evolutionarily useful structural motif that can be both constant (in structural terms) and variable (in sequence). Hence DBLs seem to have evolved using the same principles as antibody structures, where the overall 3D core structures remain the same but sequence variation in exposed residues and loop regions allows for surface diversity that can thus engage with plethora of bio-molecular receptors (Singh et al., 2006; Gill et al., 2009) . In efforts to understand the structural underpinnings Pk/Pv-DBL/DARC complex, the resolved crystal structure of Pk-DBL had suggested a region on its subdomain 2 that could accommodate the DARC's sulfated tyrosine (Singh et al., 2006) and serve as its recognition site (here referred to as Site 1, Fig 2b) . The Pk-DBL subdomain 2 presents a remarkably surface exposed region of highly conserved residues that arrange into distinct regions lying adjacent to each otherformed by positively charged residues (Lys 96, Lys 100, Arg 103 and Lys 177) and non-polars (Tyr 94, Leu 168 and Ile 175) (Singh et al., 2006) . These two dual charge/hydrophobicity character surfaces on Pk-DBL were proposed to engage with DARC's sulfated tyrosyl based on structural considerations, sequence conservation patterns, atomic properties and experimental data emanating from collation of mutagenesis experiments from two distinct groups at the time (VanBuskirk et al., 2004; Hans et al., 2005) . Further, the proposed residues on Pk-DBL were invariant in the DARC binding DBL from P. vivax, hence lending support to the proposal of their essential role in acting as a recognition site for DARC's sulfated tyrosine (VanBuskirk et al., 2004; Choe et al., 2005; Hans et al., 2005; Singh et al., 2006) . These data, coupled with the observation that the sulfated Tyr41 of DARC allows strong binding to Pk/Pv-DBLs (Choe et al., 2005) 3RRC, 4NUU and 4NUV) later identified another site for DARC binding (Fig 2a, d) , hereafter labeled Site 2, where based on (a) the binding of crystallization liquor phosphates (ostensibly 6 mimicking the sulfate of DARC's sulfated tyrosines 30 and 41), and (b) DARC peptide spanning residues 19-30, a key site for DARC binding was proposed (Batchelor et al., 2011; Batchelor et al., 2014) . In these above studies, it is to be noted that the Pk/Pv-DBLs were bacterially produced, and the DARC peptide used for co-crystallization was evidently not sulfated (see PDBs 4NUU and 4NUV). The Pv-DBL/DARC engagement was further proposed to lead to dimerization of Pv-DBL (Batchelor et al., 2011; Batchelor et al., 2014) . The existence of this DARC binding site (Site 2 in this review) was proposed based on the evidence of bound phosphates (PDB: 3RRC) at the (proposed) dimer interface of Pv-DBL (Batchelor et al., 2011) first, and then in a latter study of Pv-DBL/DARC complex, several DARC residues (numbers 19-30) were found in proximity to Site 2 (Fig 2a, d) although the bound Tyr30 was again not sulfated (Batchelor et al., 2011; Batchelor et al., 2014) . The above sets of structural and biochemical data led to a conundrum on the location of the binding site for DARC's sulfated tyrosine 41 on Pk/Pv-DBLs, and its significance in light of a previous report which had suggested that sulphation of tyrosine 41 is an essential factor for coupling of DARC with Pk/Pv DBLs (Choe et al., 2005) . We shall return to this in a later section.
It has been also proposed that Pv-DBL engagement with DARC extracellular domain drives dimerization of Pv-DBLs (PDB IDs: 3RRC, 4NUU and 4NUV) (Batchelor et al., 2011; Batchelor et al., 2014) . Extensive analysis using PISA (http://www.ebi.ac.uk/pdbe/pisa/) and EPPIC (http://www.eppic-web.org/), two softwares that analyze the oligomeric states of biomolecular structures deposited in the public database PDB (Krissinel et al., 2007; Duarte et al., 2012; Baskaran et al., 2014) , does not support dimerization of Pv-DBL when bound to phosphate or to the duffy peptide spanning residues 19-30 (we strongly encourage readers to assess this using online PISA and EPPIC softwares and the PDB: 3RRC, 4NUU and 4NUV).
However, we do not preclude the oligomerization of Pv-DBLs when bound to DARC in vivo, and/or in the context of full-length proteins of each when they interact on their respective cell surfaces. Yet from available structural data, it is evident that the Pv/Pk-DBL monomer contains all vital structural elements required for engagement with two sites on sulfated DARC.
Indications of dimeric states gathered from in solution studies like SAXS, ITC and analytical ultracentrifugation do not necessarily reveal the exact binding interfaces in a biomolecular complex. The structural resolution of Pk/Pv-EBPs bound to fully sulfated DARC will eventually reveal the modes of complex formation between these receptor ligand pairs.
A new overarching model for coupling of Pk/Pv-DBLs with DARC
The Pv-DBL (PDB: 3RRC) has two bound phosphates near/at Site 2, where later DARC peptide residues (19-30) were also found (PDBs: 4NUU, 4NUV). During process of routine structure rerefinement of deposited crystal structures, as recommended (Read et al., 2011) due to the more robust convergence routines and higher quality of resulting stereochemical models for proteins, we observed a bound sulfate at Site 1 in the Pk-DBL crystal (Fig 2a, c) . The bound sulfate site overlaps with the earlier proposed sulfa-tyrosine recognition region (Singh et al., 2006) , nestled by the highly conserved positively charged residues most of which were earlier mapped based on mutagenesis screens (VanBuskirk et al., 2004; Choe et al., 2005; Hans et al., 2005; Singh et al., 2006) . Indeed, both Pv/Pk-DBLs have other phosphate/sulfate binding sites in their crystal structures but we have taken into account only those that are proximal to the regions where mutagenesis and biochemical data provide strong evidence for DARC engagement (VanBuskirk et al., 2004; Hans et al., 2005; Sampath et al., 2013) . The Pk-DBL protein migrates as a monomer on gel filtration column in the absence of detergent, and in the crystal it is also an unambiguous monomereven when bound to a SO4 in Site 1 (see PDB ID: 5X6N and assess via 8 PISA/EPPC). The detergent binding site in 5X6N is in any case far from Sites 1 and 2 (see PDB ID: 5X6N). The presence of bound sulfate at Site 1 in Pk-DBL is clearly a striking observation, and it immediately opens the possibility of reassessing and reinterpreting the engagement rules for DARC recognition and binding by Pk/Pv-DBLs.
Therefore, based on (a) Pk-DBL-sulfate complex (Site 1, Fig. 2a, c, e ), (b) Pv-DBL-phosphate complex (Site 2, Fig. 2a, d) , (c) Pv-DBL-DARC peptide complex (Site 2, Fig. 2b, d) and
available mutagenesis and biochemical data on Pv-DBL/DARC interactions (VanBuskirk et al., 2004; Hans et al., 2005; Sampath et al., 2013) , we are able to propose a simple, novel, testable and fully rationalized resolution to the conundrum of Pk/Pv-DBL/DARC coupling (Fig. 2f, g) .
We envisage that the DARC peptide 1-60 may dock on to Pk/Pv-DBLs via its sulphated tyrosine 41 on Site 1 (Fig. 2a, f hooking on to Pk/Pv-DBLs offers a more complete binding footprint of DARC (Fig 2f, g) .
Indeed, the molecular size of a sulfated tyrosine (from its C-alpha to sulfate) is ~14Å. Quick modeling of the atomic space between Pk-DBL's Y94 (Site 1 residue, as proposed Singh et al., 2006 ) and the bound sulfate shows that a sulfated tyrosine will fit snugly into it. Further, the side chains in Pk/Pv-DBLs that constitute Site 1 are identical (4/4), and mostly (2/3) conserved for Site 2 (Fig 2 c,d) . Invariance in Site 1 residues of Pk/Pv-DBLs: Lys96, Lys100, Arg103 and Lys 177 (Pk-DBL numbering, as in Singh et al., 2006) that nestle (i.e charge complementarity) the bound sulphate moiety (Fig 2e) , and its potential as a sulfa-tyrosine recognition site based on earlier mutagenesis experiments together provide very strong support for the significance of Site 1 in Pk/Pv-DBL/DARC interactions. These analyses hence propose that both Sites 1 and 2 are part of the overall binding footprint of DARC on Pv/Pk-DBLs, and that Sites 1 and 2 likely represent the regions of engagement where sulfated Tyr41 and Tyr30 (respectively) are recognized by the Pv/Pk-DBLs (Fig 2f) . The intervening regions of Pv/Pk-DBL and DARC will also likely make contact with one another, and therefore the mutagenesis footprint on DBLs will be larger than that alone for Sites 1 and 2as indeed seems to be the case, and shall be discussed below (VanBuskirk et al., 2004; Hans et al., 2005) .
Earlier, single amino acid mutagenesis data had suggested over ~two dozen mutations that could effect binding of DARC to Pv-DBL (VanBuskirk et al., 2004; Hans et al., 2005) . Based on comprehensive collation of structural and experimental data, we now propose a model that shows that majority of the 25 mutations (VanBuskirk et al., 2004; Hans et al., 2005) that diminish Pv-DBL/DARC engagement fall in a predicted trajectory that DARC peptide may take when traversing from Site 1 from Site 2 (Figure 2f ). Two reports had earlier identified several sets of residues on Pv-DBL that altered binding to DARCseveral of these residues line and nestle the sulfate in Pk-DBL at Site 1, besides being proximal to Site 2 (VanBuskirk et al., 2004; Hans et al., 2005) . Further support for our model comes from a glycan masking study that was focused on Pv-DBL/DARC wherein it was suggested that addition of an N-glycan site near the proposed Site 1, but not in other regions of Pv-DBL, including the proposed dimer interface site (Site 2), abrogated DARC binding (Sampath et al., 2013) . These data additionally support our proposed model of twin engagement of DARC via its sulfated tyrosine 41 at Site 1 and with DARC residues 19-30 at Site 2: comprehensive mapping of mutagenesis data support our idea that DARC residues from 31 to 40 traverse from Site 2 towards Site 1 along the path where many mutants map (Fig. 2f) .
It needs to be emphasized again that our proposed model is not discounting the importance of DARC (residues 19-30) identified earlier (Tournamille et al., 2005; Batchelor et al., 2014) . Our new suggested structural framework of Pk/Pv-DBL/DARC interactions here supports, collates and integrates many studies (VanBuskirk et al., 2004; Choe et al., 2005; Hans et al., 2005; Singh et al., 2006; Batchelor et al., 2011; Batchelor et al., 2014) . Our model is consistent with most mutagenesis and crystallography work published so far, and provides a more comprehensive explanation for DARC's binding via its sulfated Tyr30 and Tyr41 to two binding sites (Sites 1 and 2) each on Pk/Pv-DBLs (Fig 2a-g) . The proposed architecture of the complex sheds new light on DBL-DARC interactions and our overview suggests avenues for experimental validation. Our proposal also offers scope to make new sets of mutants that can directly address these hypotheses using the available 3D structures.
Finally, the indicated structural framework of Pk/Pv-DBL/DARC significantly resolves the puzzle of recognition site (s) that underpin this complex. Our analyses integrate new evidence for two distinct DARC binding sites on P. knowlesi and P. vivax DBLs (called Sites 1 and 2, in the chronological order they were described in the literature) that together likely engage the extracellular domain of DARC via sulfated tyrosines 41 and 30 respectively (fig 2g) . Our analyses shall be important for critical assessment of both malaria vaccine and inhibitor development efforts that are targeted at abrogating Pk/Pv-DBL/DARC interactions as a possible avenue to prevent invasion of Pk/Pv malaria parasites into human red blood cells. a) Pk/Pv-DBL subdomains 1 (orange), 2 (green) and 3 (blue) are shown as molecular surface while the N-terminal DARC peptide is shown as ribbon (yellow for duffy residues 19-30). The bound sulfate in Pk-DBL, phosphate in Pv-DBL and DARC peptide 19-30 in Pv-DBL are shown together. Sites 1 and 2 were identified based on mutagenesis and crystallographic data on both Pv/Pk-DBLs. The Site 2 phosphate and DARC residues 19-30 in yellow are based on crystal structures as is the sulfate found at Site 1. The underlying red patches of Pv-DBL residues mark the path taken by those whose mutagenesis in two different studies effects binding of Pv-DBL with DARC. The yellow region (19-30 of DARC) is from crystal structure of Pv-DBL/DARC complex while the purple DARC represents modeling such that sulphated-Tyr41 is proximal to the sulfate observed in Pk-DBL structure. The DARC peptide can easily traverse from Tyr30 to Tyr41 as it docks on to Sites 2 and 1 respectively. b) Sequence of human DARC with tyrosyl residues 30 and 41 shown in red as these are proposed to be important for both chemokine and Pv-DBL binding. Both tyrosines 30 and 41 are sulfated in human DARC and it has been proposed that tyrosine 41 sulfation is important for high affinity Pk/Pv-DBL/DARC engagement.
